BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23246850)

  • 1. To biopsy or not to biopsy: minimizing the risk of prostate needle biopsy.
    Kibel AS
    J Urol; 2013 Mar; 189(3):796-7. PubMed ID: 23246850
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: To biopsy or not to biopsy: minimizing the risk of prostate needle biopsy: A. S. Kibel J Urol 2013; 189: 796-797.
    Horan AH
    J Urol; 2013 Sep; 190(3):1139. PubMed ID: 23583228
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply by author.
    J Urol; 2013 Sep; 190(3):1140. PubMed ID: 23770372
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare: S. Loeb, H. B. Carter, S. I. Berndt, W. Ricker and E. M. Schaeffer J Urol 2013; 189: 867-870.
    Singh I; Gautam L
    J Urol; 2013 Oct; 190(4):1439-40. PubMed ID: 23886882
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply by authors.
    J Urol; 2013 Oct; 190(4):1440. PubMed ID: 23886879
    [No Abstract]   [Full Text] [Related]  

  • 6. The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer.
    Villa L; Capitanio U; Briganti A; Abdollah F; Suardi N; Salonia A; Gallina A; Freschi M; Russo A; Castiglione F; Bianchi M; Rigatti P; Montorsi F; Scattoni V
    J Urol; 2013 Mar; 189(3):854-9. PubMed ID: 23022004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on "Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare." Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY. J Urol 2013; 189(3):867-70. [Epub 2012 Oct 9]. doi: 10.1016/j.juro.2012.10.005.
    Eggener S
    Urol Oncol; 2014 Aug; 32(6):935-6. PubMed ID: 25087672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare.
    Loeb S; Carter HB; Berndt SI; Ricker W; Schaeffer EM
    J Urol; 2013 Mar; 189(3):867-70. PubMed ID: 23063634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer polar localization on core biopsy predicts pathologic stage.
    Hensley PJ; Bailey LR; Purdom MS; Davenport DL; Strup SE
    Can J Urol; 2016 Dec; 23(6):8551-8556. PubMed ID: 27995850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Words of wisdom: re: transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer.
    Ravery V
    Eur Urol; 2013 Aug; 64(2):337. PubMed ID: 23830225
    [No Abstract]   [Full Text] [Related]  

  • 11. [The pathologist's role: to diagnose prostatic cancer and determine prognosis].
    Egevad L
    Lakartidningen; 2012 Feb 22-28; 109(8):403-6. PubMed ID: 22509665
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment.
    Labanaris AP
    J Urol; 2013 Mar; 189(3):866. PubMed ID: 23261235
    [No Abstract]   [Full Text] [Related]  

  • 13. Gleason grading of prostate cancer in needle biopsies vs. radical prostatectomy specimens.
    Vidal-Jimenez A
    Anal Quant Cytol Histol; 2006 Dec; 28(6):340-1. PubMed ID: 17225300
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Transperineal template-guided saturation biopsy using a modified technique: outcome of 270 cases requiring repeat prostate biopsy.
    Taneja SS
    J Urol; 2013 Oct; 190(4):1245-6. PubMed ID: 24029308
    [No Abstract]   [Full Text] [Related]  

  • 15. Extent of cancer of less than 50% in any prostate needle biopsy core: how many millimeters are there?
    Montironi R; Scarpelli M; Mazzucchelli R; Cheng L; Lopez-Beltran A; Montorsi F
    Eur Urol; 2012 Apr; 61(4):751-6. PubMed ID: 22239991
    [No Abstract]   [Full Text] [Related]  

  • 16. Value of transition zone biopsy in active surveillance of prostate cancer.
    Wang CC; Carter HB; Epstein JI
    J Urol; 2014 Jun; 191(6):1755-9. PubMed ID: 24316092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is an extended 20-core prostate biopsy protocol more efficient than the standard 12-core? A randomized multicenter trial.
    Irani J; Blanchet P; Salomon L; Coloby P; Hubert J; Malavaud B; Mottet N
    J Urol; 2013 Jul; 190(1):77-83. PubMed ID: 23313205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Gleason 3 + 5 = 8 Prostate Cancer Diagnosed on Needle Biopsy: Prognostic Comparison with Gleason 4 + 4 = 8.
    Harding-Jackson N; Kryvenko ON; Whittington EE; Eastwood DC; Tjionas GA; Jorda M; Iczkowski KA
    J Urol; 2016 Oct; 196(4):1076-81. PubMed ID: 27265220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer.
    Washington SL; Bonham M; Whitson JM; Cowan JE; Carroll PR
    BJU Int; 2012 Jul; 110(1):50-5. PubMed ID: 22077660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of artificial intelligence in the assessment of prostate pathology.
    Egevad L; Ström P; Kartasalo K; Olsson H; Samaratunga H; Delahunt B; Eklund M
    Histopathology; 2020 May; 76(6):790-792. PubMed ID: 32402150
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.